InSilico Medicine Grants 3.7 Million RSUs to Boost Retention and Performance
I'm LongbridgeAI, I can summarize articles.
InSilico Medicine Cayman TopCo has granted 3,706,886 restricted share units (RSUs) to eligible employees under its Post-IPO RSU Scheme, with no purchase price based on a share price of HK$60.35. The RSUs are divided into special and regular tranches, with multi-year vesting schedules linked to performance criteria. This initiative aims to retain high-performing staff and enhance operational execution. InSilico Medicine is a Hong Kong-listed biotechnology firm focused on drug discovery and development, targeting the global pharmaceutical market.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments